At first, Oasmia was started as a private research project within bioorganic chemistry in 1990. Initially, the project studied the aging of the cells but almost immediately it was decided to develop more efficient cancer treatments with less side effects than the existing treatment methods at that time.

Oasmia Pharmaceutical AB was founded in 1999.


During the period 2003/04, the majority of Oasmia’s base research regarding the Company’s oncology formulas based on XR17 was finished. In the end of 2004, clinical trials on the Company’s first product candidate, Paclical, was initiated.

During 2005, Oasmia became listed on NGM Nordic MTF. At that time, the Company had moved to its new premises adapted for its own GMP production. This year, the Company’s subsidiary Qdoxx Pharma AB was acquired. During the same period and until 2006, the investments in Paclical continued and the Company acquired 51 percent of the current Oasmia Animal Health AB. In 2006, Oasmia obtains SME status by EMA.

In 2007, Clinical phase III studies on Paccal Vet was initiated. Further, this year the new department Animal Health was established. During the autumn 2007, Oasmia changed list from NGM Nordic to NGM Equity with the aim to strengthen the liquidity in the shares of the Company. At the end of 2007, Oasmia entered into a distribution and license agreement with the Finnish company Orion Corporation regarding Paclical in the Nordic area.

In 2008, Clinical phase III studies on Paclical was initiated. At the beginning of 2008, Oasmia entered into a license agreement with Orion Corporation for Paccal Vet. Initially, the license agreement included the Nordic area as well as Poland, the Czech Republic and Hungary, but at the end of 2008 the collaboration expanded to include the major part of Europe.

In 2009, Oasmia obtained MUMS status by the FDA for Paccal Vet’s indication mastocytom grade II and III for dogs that have not obtained any treatment in the past except for treatments with cortisone. Further, during 2009 a distribution agreement was entered into with Abbott Laboratories for Paccal Vet in the US and Canada and during this year, the US Food and Drug Administration (FDA) granted Paclical orphan drug status for the treatment of ovarian cancer in the US.


Licensing agreement was entered into with Nippon Zenyaku Kogyo Co. Ltd. for Paccal Vet in Japan. Oasmia changed trading platform from NGM Equity to Nasdaq Stockholm. Oasmia submitted registration documentation for Paccal Vet to FDA.


In January, Oasmia became listed on the Frankfurt Stock Exchange.

In March, Oasmia entered into an agreement with Baxter Oncology GmbH for contract manufacturing of products, primarily Paccal Vet and Paclical.

Results from interim analysis demonstrate that Paclical meets the clinical requirement of non-inferiority vis-à-vis Taxol.


FDA was granted MUMS designation to Paccal Vet and Doxophos Vet for the treatment of mammary carcinoma and to Doxophos Vet for the treatment of lymphoma.

The Company completed an underwritten rights issue of approximately SEK 123 million.


In January, the agreement with Abbott Laboratories was expanded to include Doxophos Vet as well as to be a global collaboration, except from the rights to Paccal Vet in Russia, Japan and the Commonwealth of Independent States (CIS), and the rights to Doxophos Vet in Russia and the CIS.

In February, Oasmia signed marketing and distribution agreement for product candidate Paclical in Russia and the CIS.

In May, Oasmia initiated clinical program with Paclical in metastatic breast cancer and the Company’s patented XR17 technology generates novel cancer combination therapy.

Development of OAS-19 initiated, the first drug candidate with two active cytostatics in one infusion.

In December, the FDA confirmed that Oasmia’s manufacturing facility with respect to Paccal Vet (paclitaxel) meets the requirements of Current Good Manufacturing Practice (cGMP).


In February, Paccal Vet obtained conditional approval from the FDA.

In March, Oasmia successfully completed a private placement of approximately SEK 72 million.

In May, Oasmia’s production facility is approved by both the FDA and EMA.

In June, Oasmia’s leading product within human health, Paclical, successfully meets the primary objective in pivotal phase III clinical study.

Oasmia moved to the Mid Cap segment of Nasdaq Stockholm.


Paclical received market approval for treatment of ovarian cancer in Russia.

Oasmia regained rights to Paccal Vet and Doxophos Vet from Zoetis Inc.

Oasmia listed on Nasdaq Capital Market in New York.


Oasmia applied for market approval for Apealea (Paclical) in EU.

The Company received positive clinical results for XR17.

Oasmia applied for market approval for Doxophos in Russia.

Clinical trials on Docecal initiated.

Oasmia successfully completed a private placement of SEK 70 million.

New cancer project acquired from Karo Pharma, which was paid for by issuing shares to an amount of SEK 25 million.


Positive results for Apealea (Paclical) reported for breast cancer with weekly treatment.

The Company completed a directed share issue of approximately SEK 164 million.

The Company entered into a new exclusive marketing and distribution agreement with Hetero Group for Russia and the CIS.

Doxophos approved in Russia.

Paclical approved in Kazakhstan.


All patients treated in pivotal study on Docecal.

The Company’s veterinary assets are transferred to the American subsidiary AdvaVet Inc.

The European Commission granted approval for Apealea.

In October, Oasmia presented positive efficacy and safety data for Doxophos Vet in treatment of naïve dogs with lymphoma.

In November, a new US patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 was granted.

In November, Oasmia entered into a new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea.


The Company completed a directed share issue of approximately SEK 165 million before issue costs.

In March, Extraordinary General Meeting appoints new Board, which initiates a review of the most important areas impacting Oasmia’s value.

In March, Oasmia received positive opinion from EMA to add efficacy data to the approved Apealea product information.

During April–August, Oasmia strengthens the management team and decides to cancel the separate listing of AdvaVet.

In June, the Company reports on the results from the two clinical studies using Docecal in patients with metastatic breast cancer.

In July, Oasmia announces the formation of its Scientific and Business Advisory Boards.

In August, Oasmia is delisted from Nasdaq in the US to reduce complexity and costs.